A first-line regimen involving pembrolizumab (Keytruda) and olaparib (Lynparza) significantly reduced the risk of disease ...

The cost-effectiveness agency is assessing use of Lynparza (olaparib) in patients with tumours that carry BRCA1 or BRCA2 mutations who have previously been treated with the hormone therapies ...

AZ and Merck said that the approval makes Lynparza (olaparib) the only PARP inhibitor to have shown an improvement in overall survival when used in this setting, ahead of rivals like Clovis ...

First patient dosed in phase 1b/2a trial for castration-resistant metastatic prostate cancer, evaluating pocenbrodib alone ...

Targeted therapies for HER2-negative advanced breast cancer include: PARP inhibitors like olaparib (Lynparza) and talazoparib (Talzenna). These drugs stop a protein known as poly-ADP ribose ...

Olaparib (Lynparza, AstraZeneca) is indicated as 'monotherapy for the treatment of adult patients with germline BRCA1/2 mutations, who have HER2 negative locally advanced or metastatic breast cancer.

Full Interview Summary: The six-year follow-up data from the OlympiA trial demonstrated a 28% reduction in the risk of death with Lynparza (olaparib) for patients with germline BRCA-mutated, ...

New Delhi: The Drug Controller General of India (DCGI), Rajeev Raghuvanshi, has directed state authorities to withdraw AstraZeneca’s Olaparib Tablets, 100mg and 150mg, due to potential adverse ...

Olaparib - which is also known under the brand name Lynparza - was approved for prescription to adults with breast cancer linked to the BRCA1 gene, or those with mutated HER2-negative advanced ...